These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3055921)

  • 41. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
    Davidson M; McKenney J; Stein E; Schrott H; Bakker-Arkema R; Fayyad R; Black D
    Am J Cardiol; 1997 Jun; 79(11):1475-81. PubMed ID: 9185636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia.
    Yu WC; Chen CH; Tsao HM; Ding YA
    Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jun; 65(6):260-7. PubMed ID: 12201566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
    Walker JF; Shapiro DR
    Am J Cardiol; 1990 Mar; 65(12):19F-22F. PubMed ID: 2180267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans.
    Schectman G; Hiatt J; Hartz A
    Am J Cardiol; 1993 Apr; 71(10):759-65. PubMed ID: 8456750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
    Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
    Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
    Pierce LR; Wysowski DK; Gross TP
    JAMA; 1990 Jul; 264(1):71-5. PubMed ID: 2355431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism.
    Goldberg IJ; Holleran S; Ramakrishnan R; Adams M; Palmer RH; Dell RB; Goodman DS
    J Clin Invest; 1990 Sep; 86(3):801-8. PubMed ID: 2394831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
    Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
    Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
    [No Abstract]   [Full Text] [Related]  

  • 50. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM; Barnett MD; Wright JT; Proctor JP
    Arch Intern Med; 1992 Sep; 152(9):1781-7. PubMed ID: 1520045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
    Goldberg R; La Belle P; Zupkis R; Ronca P
    Am J Cardiol; 1990 Sep; 66(8):16B-21B. PubMed ID: 2206032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
    Schulman KA; Kinosian B; Jacobson TA; Glick H; Willian MK; Koffer H; Eisenberg JM
    JAMA; 1990 Dec; 264(23):3025-33. PubMed ID: 2123013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
    Beil FU; Schrameyer-Wernecke A; Beisiegel U; Greten H; Karkas JD; Liou R; Alberts AW; Eckardt HG; Till AE
    Cardiology; 1990; 77 Suppl 4():22-32. PubMed ID: 2073669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.